Jean-Christophe Corvol, Cécilia Bonnet, Fanny Charbonnier-Beaupel, Anne-Marie Bonnet, Marie-Hélène Fiévet, Agnès Bellanger, Emmanuel Roze, Gayané Meliksetyan, Mouna Ben Djebara, Andreas Hartmann, Lucette Lacomblez, Cédric Vrignaud, Noël Zahr, Yves Agid, Jean Costentin, Jean-Sébastien Hulot, Marie Vidailhet
OBJECTIVE: In Parkinson disease (PD), the selective C-O-methyltransferase (COMT) inhibitor entacapone prolongs the effect of levodopa on motor symptoms (ON time) by increasing its bioavailability. The COMT Val158Met polymorphism is equally distributed in PD patients and modulates COMT activity, which can be high (Val/Val, COMT(HH) ), intermediate (Val/Met, COMT(HL) ), or low (Met/Met, COMT(LL) ). The objective of this study was to determine the response to entacapone in COMT(HH) and COMT(LL) PD patients...
January 2011: Annals of Neurology